November 18, 2020 Stoke Therapeutics, Inc., a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein

The partnership will enable co-development of treatment planning tools that integrate the cloud-based Paige Platform with genomic information from Agendia’s proprietary MammaPrint® and BluePrint® diagnostic tests for patients with breast cancer. These new products will enable faster access to predictive and prognostic information along the entire continuum of care, from diagnosis and early intervention to metastatic treatment planning.

TissueCypher Barrett’s Esophagus Assay independent peer-reviewed studies, are authored by Prof. Jacques Bergman and Dr. Nicola Frei (University Medical Center, Amsterdam, the Netherlands).

The SARS-CoV-2 Plus ELITe MGB Assay is developed and manufactured in Bothell, Wash., and it uses RNase P as an endogenous control for increased test reliability.

The new data demonstrates the increasing prevalence of essential tremor (ET) from 2010 to 2018; a high rate of depression and anxiety in patients with ET; and the safety and efficacy of Cala Trio when used in a real-world setting to treat ET.

SOFIE notes following U.S. Food and Drug Administration (“FDA”) approval, Lantheus will have a critical need for dependable and scalable manufacturing and distribution partners to support PyL™.